Q1 2025 Aethlon Medical Inc Earnings Call Transcript
Key Points
- Aethlon Medical Inc (AEMD) has received full ethics approval for a clinical trial of its Hemopurifier in Australia, which is a significant step forward in its oncology research.
- The company has successfully reduced its operating expenses by approximately 24% compared to the previous year, demonstrating effective cost management.
- Aethlon Medical Inc (AEMD) has a solid cash balance of approximately $9.1 million as of June 30, 2024, providing a stable financial foundation for ongoing operations.
- The Hemopurifier has shown potential in preclinical studies to reduce extracellular vesicles, which may improve therapeutic response rates to anti-PD-1 therapies.
- The company is poised to address outbreaks and pandemics with its Hemopurifier, which has demonstrated the ability to bind and remove life-threatening envelope viruses in vitro.
- The company's net loss for the fiscal quarter ended June 30, 2024, was approximately $2.6 million, indicating ongoing financial challenges.
- Aethlon Medical Inc (AEMD) has only treated one patient in its COVID-19 trial in India, suggesting slow progress in this area.
- There is an expectation of increased expenses related to clinical trials in Australia, which may offset recent cost reductions.
- The company is still awaiting approvals from research governance offices, which could delay the start of patient enrollment in clinical trials.
- Only approximately 30% of patients respond to current anti-PD-1 therapies, highlighting the challenge of improving therapeutic outcomes with the Hemopurifier.
Good day, and welcome to the Aethlon Medical fiscal first quarter 2025 earnings and corporate update conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Michael Miller of Rx Communications. Please go ahead.
Thank you, operator, and good afternoon, everyone. Welcome to Aethlon Medical's fiscal first quarter 2025 earnings conference call. My name is Michael Miller with Rx Communications. At 4:15 PM Eastern Time today, Aethlon Medical released financial results for its fiscal first quarter ended June 30, 2024. If you have not seen or received Aethlon Medical's earnings release, please visit the Investors page www.aethlonmedical.com.
Following this introduction and the reading of the company's forward-looking statement disclaimer, Aethlon's Interim Chief Executive Officer and Chief Financial Officer, James Frakes, and Aethlon's Chief Medical Officer, Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
